首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1623512

心臟標記測試市場：依產品類型、生物標記類型、應用、地區劃分，2024-2031

Cardiac Marker Testing Market By Product, Biomarker Type (Troponin I & T, Creatine Kinase-MB, Natriuretic Peptide, Myoglobin, High-Sensitivity C-Reactive Protein), Application, & Region for 2024-2031

出版日期: 2024年08月16日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

心臟標記測試市場評估，2024-2031

心血管疾病發生率的增加以及對早期檢測和預防工作的瞭解不斷增加，推動了對心臟標記檢測解決方案的需求。Verified Market Research 分析師表示，2023 年心臟標記檢測市場估值約為 44.2 億美元，預計在預測期內將達到 86.9 億美元。

由於老年人口的增加、生活方式的改變、肥胖和糖尿病等危險因素的增加以及對心臟標記測試等先進診斷技術的需求激增，2024年至2031年該市場將以8.8%的複合年增長率增長。

心臟標記測試市場定義/概述

心臟標記測試分析由於心肌損傷或壓力而釋放到血液中的特定蛋白質。肌鈣蛋白、肌酸激酶 MB (CK-MB) 和肌紅蛋白是心臟損傷的指標，可以幫助診斷各種心血管疾病，包括心臟病發作、心肌梗塞和不穩定型心絞痛。心臟標記測試最常用於急性冠狀動脈綜合徵的早期檢測、診斷和風險分層，使醫療保健專業人員能夠盡快啟動適當的治療和乾預措施。

此外，心臟標記檢測對於監測已知心血管疾病的患者、評估治療效果和確定治療策略至關重要。在急診室、重症監護病房和門診環境中的廣泛使用表明了其在改善患者預後和降低心臟事件死亡率方面的重要性。

心臟病的流行將如何推動心臟標記檢測市場的成長？

全球心血管疾病（如心臟病、中風和其他心臟相關疾病）的增加是心臟標記檢測市場的主要推動因素。由於心血管疾病仍然是全世界死亡的主要原因，人們越來越渴望早期、準確的診斷，這可以透過心臟標記測試來幫助。這些測試對於確定心臟病的嚴重程度和建議治療至關重要。

即時檢測技術的發展和增強正在對心臟標記檢測市場產生重大影響。POCT 可以在患者治療時或附近進行快速診斷測試，從而能夠及時做出決策並開始治療。心臟標記POCT方便、快速、高效，使急性冠狀動脈症候群（ACS）和其他心臟病患者受益，支持市場成長。

此外，人們對心臟病及其危險因子的認識不斷提高，因此越來越需要預防性護理和早期檢測，包括使用心臟標記。此外，全球醫療保健支出的增加，特別是在較貧窮的國家，也增加了獲得改進的診斷工具的機會。政府和醫療機構正在投資醫療基礎設施和服務，包括診斷，這正在推動心臟標記測試市場的發展。

嚴格的審批程序是否會阻礙心臟標記檢測解決方案的採用？

新心臟標記檢測技術的開發和採用存在一些操作障礙，包括對先進檢測設備的大量財務投資和醫療專業人員的培訓。此外，確保測試結果的準確性和可靠性很困難，特別是在醫療點環境和資源匱乏的環境中，現代診斷設施的使用有限，這限制了市場的成長。

新的心臟指標和測試的監管審批流程非常嚴格，並且因地區而異。獲得美國FDA（美國食品藥物管理局）和歐洲EMA（歐洲藥品管理局）等機構的監管批准需要臨床驗證和有效性證據；耗時且成本高昂，限制了市場拓展。

此外，與傳統技術相比，與使用心臟市場測試相關的技術複雜性是全球接受的主要障礙。同樣，心臟市場測試解決方案的持續維護要求和高成本限制了面臨預算限制的製造商的採用。

The increasing frequency of cardiovascular diseases, along with growing knowledge of early detection and prevention efforts, is driving demand for cardiac marker testing solutions. According to the analyst from Verified Market Research, the cardiac marker testing market is estimated to reach a valuation ofUSD 8.69 Billion over the forecast subjugating around USD 4.42 Billion valued in 2023.

Growing elderly population, lifestyle changes is increasing risk factors including obesity and diabetes, surging demand for advanced diagnostic technology, such as cardiac marker testing, enabling the market to grow at a CAGR of 8.8% from 2024 to 2031.

Cardiac Marker Testing Market: Definition/ Overview

Cardiac marker testing analyses specific proteins released into the bloodstream as a result of heart muscle damage or stress. Troponin, creatine kinase-MB (CK-MB), and myoglobin are indications of cardiac injury that aid in the diagnosis of a variety of cardiovascular disorders, including heart attacks, myocardial infarctions, and unstable angina. Cardiac marker testing is most commonly used for the early detection, diagnosis, and risk stratification of acute coronary syndromes, allowing healthcare providers to commence relevant therapies and interventions as soon as possible.

Furthermore, cardiac marker testing serves as essential for monitoring patients with known cardiovascular illnesses, evaluating treatment efficacy, and directing therapeutic decisions. Its broad use in emergency rooms, critical care units, and ambulatory settings demonstrates its importance in improving patient outcomes and lowering mortality rates from cardiac events.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will Prevalence of Cardiac Illnesses Bolster Growth of Cardiac Marker Testing Market?

The global rise in cardiovascular disorders, such as heart attacks, strokes, and other heart-related conditions, is a major driver of the cardiac marker testing market. As cardiovascular disease remains one of the top causes of death worldwide, there is an increased desire for early and precise diagnosis, which can be aided by cardiac marker testing. These tests are crucial in determining the severity of heart problems and making treatment recommendations.

The development and enhancements to point-of-care testing technology have significantly impacted the cardiac marker testing market. POCT enables quick diagnostic testing at or near the point of patient care, allowing for timely decision-making and treatment commencement. POCT for cardiac markers is convenient, fast, and efficient, which benefits patients with acute coronary syndromes (ACS) and other heart problems, supporting market growth.

Furthermore, increased awareness of heart disease and its risk factors is resulting in a greater need for preventative care and early detection, including the use of cardiac markers. Also, increased worldwide healthcare expenditure, particularly in poorer nations, is increasing access to improved diagnostic tools. Governments and healthcare organizations are investing in healthcare infrastructure and services, including diagnostics, which is helping to drive the cardiac marker testing market.

Will Strigent Approval Procedures Restrain Adoption of the Cardiac Marker Testing Solutions?

The development and adoption of new cardiac marker testing technologies encounter several operational hurdles, including a significant financial investment in sophisticated testing equipment and healthcare professional training. Also, assuring the accuracy and reliability of test results is difficult, especially in point-of-care settings or low-resource environments with limited access to modern diagnostic facilities, which restricts market growth.

The regulatory approval process for new cardiac indicators and testing methods is stringent and varies greatly between regions. Obtaining regulatory authorization from agencies such as the FDA (US Food and Drug Administration) in the United States or the EMA (European Medicines Agency) in Europe demands significant clinical validation and evidence of efficacy, which is time-consuming and expensive, limiting market expansion.

Also, the technical complexity associated with the use of cardiac market testing compared to the legacy technologies is creating a major barrier for its acceptance worldwide. Similarly, the need for constant maintenance and high cost of the cardiac market testing solutions is restraining the adoption among manufacturers facing budget constraints.

Category-Wise Acumens

What Factors Contribute to the Dominance of Reagents & Kits Segment in the Market?

According to VMR analysis, the reagents & kits segment is estimated to hold the largest market share in the product segment during the forecast period. Reagents and kits are consumables used in a large number of tests for cardiovascular disease diagnosis, monitoring, and management. Unlike instruments, which are less frequent capital investments, reagents and kits must be replenished constantly. Their higher market share is due to their recurring use, which is driven by the ongoing demand for cardiac marker testing in hospitals, diagnostic laboratories, and point-of-care settings.

Ongoing research and development in the field of cardiovascular diseases is resulting in the identification of new biomarkers as well as improvements in test sensitivity and specificity. This advancement needs the continual update and purchase of new or improved reagents and kits capable of detecting these markers, resulting in high demand and market dominance.

Furthermore, reagents and kits are intended for convenience of use and ease in integration into existing laboratory processes without requiring significant additional investment in new equipment or training. Their simplicity of integration makes them an appealing option for many healthcare professionals.

Which Variables Lead to the Broad Acceptance of Point-of-Care Testing?

The point-of-care testing (POCT) segment is estimated to grow at the highest CAGR in the cardiac marker testing market during the forecast period. POCT facilities provide testing closer to the patient, whether at the bedside, in ambulatory care settings, or community clinics, minimizing the need to send samples to centralized laboratories. This greater accessibility is especially useful in emergencies, where early detection is important for managing acute cardiac events like myocardial infarction. The ease of obtaining quick findings without the requirement for complex laboratory infrastructure makes POCT very appealing.

The short turnaround time of results from point-of-care cardiac marker tests allows for urgent clinical decision-making. In the case of cardiovascular disorders, time is of the essence, and the ability to diagnose and commence therapy swiftly can have a substantial impact on patient outcomes. This promptness can lead to better management of patients with acute cardiac problems, shorter hospital stays, and increased overall healthcare efficiency.

Furthermore, technological advances have greatly increased the accuracy, reliability, and range of POCT for cardiac indicators. Modern point-of-care devices can provide laboratory-quality data for important biomarkers like troponin, natriuretic peptides, and others right at the patient's side. These developments have also made POCT devices more user-friendly and cost-effective, accelerating their adoption in a variety of healthcare settings.

Country/Region-wise Acumens

What Factors help Shape Growth of the Market in North America?

According to VMR analyst, North America is estimated to dominate the cardiac marker testing market during the forecast period. North America has one of the highest rates of cardiovascular disease in the world, owing to an ageing population, lifestyle-related risk factors (such as obesity, physical inactivity, and an unhealthy diet), and a high incidence of comorbid conditions (such as diabetes and hypertension). This high prevalence of CVDs causes a significant demand for early and precise diagnosis, monitoring, and management, which is supporting the region's cardiac marker testing market expansion.

Furthermore, North America, particularly the United States, has a well-developed healthcare infrastructure, with a strong emphasis on innovative diagnostic technology and treatments. This infrastructure enables the widespread availability of cardiac marker testing in a variety of healthcare settings, ranging from top-tier hospitals to community clinics. The availability of cutting-edge medical facilities, together with a robust network of laboratories and point-of-care testing facilities, provides wider access to cardiac marker tests, hence driving their uptake and utilization.

How will Cardiac Marker Testing Market Fare in Asia Pacific?

Asia Pacific is experiencing an increase in prevalence of cardiovascular disease as a result of changing lifestyles, urbanization, and ageing populations. Increased tobacco use, poor diets, and physical inactivity all contribute to a rise in the prevalence of heart disease. The growing incidence of CVDs needs early detection and therapy is driving demand for cardiac marker testing in the region.

Furthermore, countries in Asia Pacific are making considerable investments in healthcare infrastructure, such as hospitals, clinics, and diagnostic centers. This expansion is fueled in part by increased economic capacities and a focus on increasing healthcare access and quality. Access to modern diagnostic techniques such as cardiac marker tests grows in tandem with healthcare infrastructure improvements. This rise is especially evident in emerging economies like China and India, where the healthcare industry is rapidly modernizing and expanding.

Competitive Landscape

The competitive landscape of the cardiac market testing market is defined by a dynamic interplay between numerous companies that strive to develop novel solutions that meet the changing needs of patients and healthcare providers. These players are always researching and developing ways to improve the accuracy, efficiency, and accessibility of cardiac testing devices.

Some of the prominent players operating in the cardiac marker testing market include:

Abbott Laboratories

Hoffmann-La Roche Ltd.

Siemens Healthineers AG

Danaher Corporation

Ortho-Clinical Diagnostics

Beckman Coulter Inc.

bioMerieux SA

Koninklijke Philips N.V.

Trinity Biotech plc

Mercadia BioSciences Inc.

LSI Medience Co., Ltd.

Mindray Medical International Limited

Shenzhen Mindray Bio-Medical Electronics Co.

EKF Diagnostics Holdings plc

DiaSorin S.p.A.

Hytest Limited

Stanbio Laboratory LLC

Streck

Thermo Fisher Scientific Inc.

Latest Developments

In February 2024, Abbott announced the ARCHITECT Myxovirus Multiplex Assay, which detects numerous respiratory viruses at the same time, including influenza A and B, respiratory syncytial virus (RSV), and parainfluenza viruses. This assay can aid healthcare practitioners in distinguishing between cardiac difficulties and respiratory infections, which can sometimes present with identical symptoms.

In February 2024, Siemens Healthineers obtained FDA approval for its Atellica(R) CH SOAPS Assay, a novel test that detects creatine kinase-MB (CK-MB), an important cardiac marker. This assay is specifically developed to be used on the Atellica(R) CH immunoassay analyzer, which provides shorter turnaround times and increased workflow efficiency.

In January 2024, Danaher Corporation, which owns Beckman Coulter, announced the acquisition of PHC Holdings Corporation, a major global manufacturer of life science equipment. This acquisition is expected to boost Danaher's position in the cardiac marker testing market by providing them with a more diverse array of diagnostic solutions.

1 INTRODUCTION OF GLOBAL CARDIAC MARKER TESTING MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CARDIAC MARKER TESTING MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL CARDIAC MARKER TESTING MARKET, BY PRODUCT

5.1 Overview
5.2 Instruments
5.3 Reagents and Kits
5.4 Immunofluorescence
5.5 Elisa
5.6 Immunochromatography

6 GLOBAL CARDIAC MARKER TESTING MARKET, BY TYPE

6.1 Overview
6.2 Troponin I and T
6.3 CK-MB
6.4 Myoglobin
6.5 Other Biomarker

7 GLOBAL CARDIAC MARKER TESTING MARKET, BY TYPE OF TESTING

7.1 Overview
7.2 Laboratory Testing
7.3 Point-Of-Care Testing

8 GLOBAL CARDIAC MARKER TESTING MARKET, BY DISEASE

8.1 Overview
8.2 Myocardial Infarction
8.3 Congestive Heart Failure

9 GLOBAL CARDIAC MARKER TESTING MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL CARDIAC MARKER TESTING MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Roche Diagnostics Limited
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Abbott Laboratories
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Siemens AG
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Danaher Corporation
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 BiomA(C)rieux SA
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Alere Inc.
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 LSI Medience Corporation
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Ortho Clinical Diagnostics
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Randox Laboratories Ltd
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Guangzhou Wondfo Biotech Co., Ltd.
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments